European Psychiatry - Volume 41 - April 2017

279 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302 S275
– scored 1-2 on the Clinical Global Impression Scale;
– showed a greater than 25% reduction of the total score on the
Positive and Negative Syndrome Scale (PANSS) or a greater than
20% reduction on the negative subscale of PANSS.
Forty-seven patients were randomized: treatment group (neu-
roleptic +memantine, n = 24), control group (neuroleptic + placebo,
n = 23); 44 patients completed the study. Neither memantine
nor placebo led to a reliable decrease of negative symptoms,
and the groups did not differ from each other. Future studies
should pay more attention not only to the treatment of already
formed negative and cognitive symptoms, but the prevention of
their occurrence. Including through antagonists of N-methyl-d-
aspartate receptors.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0496
Cannabis use in a first onset psychosis
sample: Prevalence and clinical
differences in relation to age of onset
M. Pardo ∗, J. Matalí , A. Butjosa , V. Regina , M. Dolz ,
J. Usall
1 Hospital Sant Joan de Déu, Child and Adolescent Psychiatry,
Barcelona, Spain
2 Parc Sanitari Sant Joan de Deu, Unitat de Recerca i
Desenvolupament, Sant Boi de Llobregat, Spain
∗ Corresponding author.
Introduction There is a wide range of studies focusing on the use
of cannabis in first episode psychosis (PEP). Literature using child
and adolescent samples is scarce.
Objectives and aims To determine the prevalence and clinical dif-
ferences between cannabis users and non-cannabis users of early
onset first episode psychosis (EOP), and adult onset first episode
psychosis (AOP).
Method One hundred and forty patients were recruited in adult
(AOP subsample, n = 69) and child and adolescent (EOP subsample,
n = 71) mental health services. The Positive and Negative Syndrome
Scale was used for psychotic symptoms and the Calgary Scale
for affective symptoms. The Chi2 test analysed clinical differences
between users and nonusers within subsamples, and in the total
sample a Pearson correlationwas used for the relationship between
age at cannabis use and PEP.
Results The prevalence of lifetime use of cannabis and the aver-
age age at first use were 48% and 13.82 years (±1.15) in the EOP
subsample, and 58% and 17.78 years (±3.93) in the AOP subsample.
Within EOP, cannabis users were older (P = .001), had fewer nega-
tive symptoms (P = .045) and less depressive symptoms (P = .005).
Within AOP, cannabis users were younger (P = .018) and had greater
severity of positive symptoms (P = .021). Age at first cannabis use
and age at PEP were positively correlated.
Conclusions Cannabis use is prevalent in adult and early onset
psychosis. Cannabis users differ clinically from non-users, and the
earlier the use of cannabis, the earlier the onset of psychosis.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0497
The regional project for the treatment
of early psychosis implemented in the
Reggio Emilia Mental Health
Department: Preliminary data from a
2-year follow-up
L. Pelizza∗, A. Raballo , E. Semrov , S. Azzali , S. Garlassi ,
F. Paterlini , I. Scazza , F. Fontana , R. Favazzo , M. Fabiani ,
L. Pensieri , V. Barbanti Silva , L. Cioncolini
Reggio Emilia Public Health Service, Reggio Emilia Department of
Mental Health, Reggio Emilia, Italy
∗ Corresponding author.
Introduction Several studies had shown the effectiveness of com-
bined interventions in the treatment of young patients with a first
episode of psychosis (FEP). More controversial are the evidence
about the stability of the therapeutic outcomes in individuals ultra-
high risk (UHR).
Aims To describe the regional project for the treatment of early
psychosis implemented in the Reggio EmiliaMental Health Depart-
ment (ReMHD) and also to report preliminary data from a 2-year
follow-up.
Methods In addition with the treatment as usual (TAU), treat-
ment implemented within the regional project for early psychosis
(PREP) in the ReMHD comprises the following:
– pharmacotherapy according to international guidelines;
– a phase-specific individualized Cognitive-Behavioural therapy;
– a psycho-educational intervention addressed to familymembers;
– a case management recovery-oriented.
Action strategies are preceded by the administration of Reggio
Emilia at Risk mental States Battery Checklist as a comprehensive
assessment useful to define the severity and the quality of symp-
toms, the degree of functioning, the subjectivity of suffering, and
the perceived quality of life.
Results The assessment carried out after 24months of continuous
treatment showed significant improvements in both the psychotic
symptoms (positive, negative and general psychopathology PANSS
subscales) that the daily functioning (SOFAS).
Conclusions Although our sample is still relatively small (n = 50)
to draw definitive conclusions, it is emerging the good progno-
sis for UHR individuals and patients with FEP submitted on PREP
treatment implemented in the ReMHD.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0498
Neuropsychological profile of specific
executive functions in patients with
deficit and non-deficit schizophrenia
J. Pelka-Wysiecka ∗, T. Ernest , M. Monika , S. Jerzy
1 Pomeranian Medical University, Psychiatry, Szczecin, Poland
2 University of Szczecin, Department of Clinical Psychology- Institute
of Psychology, Szczecin, Poland
3 Pomeranian Medical University, Independent Clinical Psychology
Unit- Department of Psychiatry, Szczecin, Poland
∗ Corresponding author.
Although it has been shown that there are more profound deficits
present in the deficit schizophrenia (DS) patients compared with
their non-deficit (NDS) counterparts, there still remain a few mat-
ters that require further investigation.
Aims (1) Comparison of executive functions between the inves-
tigated groups; (2) determining the relationship between their
particular aspects within the groups; and (3) drawing up their neu-
ropsychological profile.
Methods One hundred and forty-eight schizophrenia patients,
divided into two groups: patients with DS (n = 70) and NDS (n = 78).
Patients were matched for sex, age, number of years of education
and their overall cognitive functioning. For the assessment of exec-
utive function, we used the Wisconsin Card Sorting Test (WCST),
the Trail Making Test (TMT), Verbal Fluency Test Phonemic (VFT P),
Stroop Color Word Test (SCWT) and Go/No Go task (GNG).
Results The DS patients compared with the NDS ones obtained
lower scores in WCST and TMT (relative flexibility). We did not